Clinical Trials on Relapsed/Refractory Burkitt Lymphoma in Belgium

Total 58 results

Amgen

Completed

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. (CANDOR)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

Canada, Belgium, Spain, United States, Korea, Republic of, Australia, Czechia, Taiwan, Hungary, Austria, Romania, Japan, United Kingdom, Greece, Turkey, Bulgaria, France, Russian Federation, Poland
Millennium Pharmaceuticals, Inc.

Completed

A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

United States, France, Norway, Spain, Israel, United Kingdom, Italy, Australia, Germany, Greece, Canada, Czechia, Turkey, Russian Federation, Denmark, Sweden, Belgium, Netherlands
Janssen Research & Development, LLC

Recruiting

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)

Relapsed or Refractory Multiple Myeloma

United States, Canada, Australia, China, Germany, Belgium, Malaysia, Turkey, Japan, Israel, Sweden, Spain, United Kingdom, Czechia, Denmark, Brazil, Italy, France, Netherlands, Poland, Austria, Portugal, Greece, India
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (MonumenTAL-3)

Relapsed or Refractory Multiple Myeloma

United States, Italy, Korea, Republic of, Taiwan, China, Germany, Turkey, Japan, France, United Kingdom, Brazil, Spain, Czechia, Poland, Israel, Belgium, Greece, Netherlands
Celgene

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

Relapsed or Refractory Multiple Myeloma

United States, Australia, Italy, China, Spain, Germany, Romania, Korea, Republic of, Japan, United Kingdom, Czechia, Finland, France, Greece, Argentina, Belgium, Austria, Portugal, Israel, Poland, Brazil, Turkey, Canada, Ireland, New Zealand and more
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic CLL Study Group

Active, not recruiting

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Chronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in Remission

Netherlands, Belgium, Denmark, Finland, Norway, Sweden
Sandoz

Completed

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor (Monitor-GCSF)

B-cell Lymphoma | Cancer | Breast Cancer | Multiple Myeloma | Ovarian Cancer | Lung Cancer | Febrile Neutropenia | Prostate Cancer | Bladder Cancer

Germany, Italy, Poland, Hungary, Romania, Austria, Belgium, Czech Republic, France, Spain, Switzerland, United Kingdom
Hoffmann-La Roche

Active, not recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

Melanoma | Renal Cell Carcinoma | Adult Solid Tumor | Breast Cancer | Head and Neck Neoplasms | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Tumors | Lymphoma, Large-Cell, Anaplastic | Cholangiocarcinoma | Papillary Thyroid Cancer | Sarcomas | Salivary Gland Cancers and other conditions

United States, China, Korea, Republic of, Australia, Taiwan, France, Spain, United Kingdom, Hong Kong, Belgium, Italy, Germany, Japan, Singapore, Netherlands, Poland

Clinical Trials on Relapsed/Refractory Burkitt Lymphoma in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations